Holen Sie sich die Stockscreener-App
30.07
7.53%
-2.45
Hemab Therapeutics Holdings Inc Aktie (COAG) Neueste Nachrichten
Hemab Therapeutics (NASDAQ:COAG) Stock Price Up 8.4%Here's What Happened - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Stock Price Down 7.5%What's Next? - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount? - Yahoo Finance
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount? - Yahoo Finance UK
76,900 Shares in Hemab Therapeutics Holdings, Inc. $COAG Bought by State Street Corp - MarketBeat
Form 4 Hemab Therapeutics Holdings For: 25 September - Investing.com India
Form 4 Hemab Therapeutics Holdings For: 25 September By Investing.com - Investing.com Canada
Form 4 Hemab Therapeutics Holdings For: 25 September By Investing.com - Investing.com UK
Director Walbert Keli's option carries a $35.72 exercise price at Hemab Therapeutics (COAG). - stocktitan.net
Hemab Therapeutics Holdings, Inc. (COAG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Can Hemab Therapeutics Holdings (COAG) Justify Its Valuation After Russell Index Inclusion? - Simply Wall Street
Hemab Therapeutics (NASDAQ:COAG) Shares Down 5.7%What's Next? - MarketBeat
Hemab Therapeutics Holdings (Nasdaq:COAG)Stock Analysis - simplywall.st
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to Russell 3000 Value Benchmark - marketscreener.com
Heavy menstrual bleeding affects 1 in 3 women. Hemab begins testing a new treatment. - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Shares Up 7.6%Time to Buy? - MarketBeat
Opaleye Management Inc. Makes New Investment in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Trading Down 6.8%What's Next? - MarketBeat
Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Braidwell LP Purchases New Shares in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Biopharma IPO class of 2026: share price up 66% on average - BioWorld News
Hemab Therapeutics (NASDAQ:COAG) Trading Down 8.4%Here's What Happened - MarketBeat
AppLovin vs. CoreWeave: What Recent Revenue Trends Tell Investors - Yahoo Finance
Capital International Investors Establishes New Position in Hema - GuruFocus
Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics - Stock Titan
Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake - Stock Titan
20 Years of Prix Galien USA Brings a New Nominee Class—Who Wins? - Stock Titan
HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics - MarketBeat
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership - Stock Titan
Hemab Therapeutics stock price target raised to $60 by H.C. Wainwright - Investing.com Canada
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
FMR LLC Acquires Stake in Hemab Therapeutics Holdings Inc (COAG) - GuruFocus
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Hemab Therapeutics Reports Q2 2026 Financials and Pipeline Progress in Latest 10-Q Filing - Kalkine Media
Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating - marketscreener.com
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com South Africa
Hemab Therapeutics Gains FDA Backing to Advance Sutacimig Into Phase 3 Trial for Glanzmann Thrombasthenia - Minichart
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com Nigeria
Hemab Therapeutics' Q2 Net Loss Narrows - marketscreener.com
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com Canada
Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
7.09%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):